Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

Have you been diagnosed with s Cutaneous (skin) Lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. Such a registry would collect information such as the specific cutaneous lymphoma diagnosis, stage of disease, treatments used, and response to treatments. This information will collected on an online Institutional Review Board (IRB)-approved database/registry of patients from all sites. We hope that this will allow providers to better understand this rare disease by looking at data from many patients. We hope ultimately will include all the patients with cutaneous lymphoma across the United States

Have you been histologically or cytologically confirmed to have Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies? If so, you may be able to participate in a research study seeking to find out if Amivantamab Monotherapy and/or Amivantamab in Addition to Standard of Care Therapeutic Agents can be an effective traetment.

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

Are you a male that has been diagnosed with hormone receptor positive and HER2 negative breast cancer? If so, you may be eligible to a clinical trial comparing different endocrine therapies to treat breast cancer prior to surgery.

Have you been diagnosed with metastatic breast cancer? If so, you may be able to take part in a research study looking at the efficacy of giving a drug called enzalutamide, alone or combined with mifepristone vs standard chemotherapy.

Have you been diagnosed with Smoldering Multiple Myeloma (SMM)? Are you 40 years old or older? If so, you may be able to participate in a study to see if AL-related genes can increase the chances of SMM patients developing AL Amyloidosis in the future.

Have you been diagnosed with metastatic breast cancer? If so, you may be able to take part in a research study looking at the safety and efficacy of giving a new drug called DB-1303 vs standard chemotherapy to patients with metastatic breast cancer.

Are you dealing with multiple myeloma that keeps coming back or hasn't improved? If you are, you may be able to join a study to see if a new drug called ABBV-383 could be safe and helpful for people in your situation. You will be reimbursed for travel expenses. You will not have to pay for the drug while you take part in this study.

Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL) that has transformed to aggressive lymphoma called Richter's Transformation (RT)? Then you may be able to participate in this study whose purpose is to evaluate the efficacy and safety of glofitamab as monotherapy and in combination with polatuzumab vedotin or atezolizumab for participants with Richter's Transformation (RT) that has transformed from chronic lymphocytic leukemia (CLL). These are targeted immune-based therapies standardly used to treat lymphoma and/or other cancers that may also work well for RT